What is Triple-H Therapy?
Triple-H therapy is a historically used but now largely abandoned hemodynamic strategy consisting of induced hypertension, hypervolemia, and hemodilution that was employed to prevent and treat delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage, but current evidence shows it lacks proven efficacy and carries significant risks of serious complications. 1
Historical Rationale
Triple-H therapy was developed based on the observation that cerebral vasospasm after SAH was associated with hypovolemia. The theoretical mechanism was to improve cerebral perfusion through three components:
- Hypertension: Elevating blood pressure to overcome vasospasm and increase cerebral blood flow
- Hypervolemia: Volume expansion to prevent hypovolemia
- Hemodilution: Reducing blood viscosity to improve microcirculatory flow
This approach became the mainstay of medical prevention and treatment of DCI for decades, despite never having supporting evidence from randomized controlled trials 1.
Current Evidence Against Triple-H Therapy
Lack of Efficacy
A systematic review showed no evidence from controlled studies for a positive effect of triple-H therapy or its separate components on cerebral blood flow in SAH patients 1. The HIMALAIA trial, which tested induced hypertension in patients with DCI symptoms, was stopped prematurely due to futility—despite achieving higher mean arterial pressure, there was no statistical difference in cerebral blood flow between intervention and control groups 1.
Significant Complications
Uncontrolled studies reported serious adverse events in up to 50% of patients, including 1:
- Cardiac arrhythmia
- Pulmonary edema
- Hemorrhagic transformation
- Intracranial bleeding
- Death in up to 25% of patients
The HIMALAIA trial showed a trend toward more serious adverse events with induced hypertension (odds ratio 2.1,95% CI 0.9-5.0) 1.
Current Recommended Approach
Modern guidelines have shifted away from triple-H therapy to a more targeted strategy 2, 3:
Maintenance of Euvolemia (Not Hypervolemia)
- Avoid hypovolemia, but hypervolemia confers no additional benefit and increases complications 2
- Monitor volume status and treat volume contraction with isotonic fluids 2
Induced Hypertension Only (Not Triple-H)
- When DCI is diagnosed, induced hypertension alone may be reasonable 2, 3
- Hypertension appears more effective than hemodilution or hypervolemia at increasing cerebral blood flow 1
- Target blood pressure according to neurological response 4
Proven Effective Therapy
- Oral nimodipine remains the only Class I evidence-based treatment that improves neurological outcomes 2
Clinical Pitfalls
The term "triple-H therapy" persists in medical literature and practice despite evidence showing:
- Hypervolemia is unnecessary and potentially harmful with excess side effects 5
- Hemodilution has no proven benefit for cerebral blood flow 1
- Only the hypertension component showed any suggestion of benefit in uncontrolled studies 1
The appropriate modern terminology is "hemodynamic augmentation" or "induced hypertension," not triple-H therapy 2. Clinicians should avoid prophylactic hypervolemia and focus on maintaining euvolemia with selective use of induced hypertension only when DCI develops 2, 4, 3.